Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Aug
16
Today In Oncology
What Is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy
Can Newborn Genetic Testing Identify Cancer Predisposition Genes
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
QOL Impact of Postmastectomy Chest Wall Radiotherapy 5-Year Follow-up
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo